Study of NVN1000 Topical Gel and Topical Gel Vehicle in the Treatment of Moderate to Severe Acne Vulgaris
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The primary objective of this study is to compare the tolerability, safety and efficacy of NVN1000 Topical Gel and Topical Gel Vehicle in the treatment of subjects with moderate to severe acne vulgaris.
Condition or disease
Drug: NVN1000 Topical GelDrug: Topical Gel Vehicle
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
12 Years to 40 Years (Child, Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Baseline IGA score of moderate (3) or severe (4)
Minimum of 20 but no more than 40 facial inflammatory lesions
Minimum of 20 but not more than 60 facial non-inflammatory lesions
No more than 2 facial nodules
Dermatological conditions on the face that could interfere with clinical evaluations
Underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive
History of experiencing significant burning or stinging when applying any facial treatment
Female subjects, if they are pregnant,nursing mothers, or planning to become pregnant during the study
Have used estrogens or oral contraceptives for less than 90 days immediately preceding the Baseline visit, discontinued use of estrogens or oral contraceptives less than 90 days prior to Baseline,or planning to begin or discontinue use of this therapy during the treatment period
Have used medications and/or vitamins which are reported to exacerbate acne during the 180 days immediately preceding the Baseline visit
Use concomitantly over-the-counter (OTC) products that contain ingredients such as benzoyl peroxide,salicylic acid,alpha-hydroxy acid,retinol or glycolic acids
Have not undergone the specified washouts for topical preparations,systemic medications and procedures noted in the protocol